The result was announced after market hours on Tuesday, 5 February 2013.

Meanwhile, the BSE Sensex was up 9.79 points, or 0.05%, to 19,669.61.

On BSE, 1.63 lakh shares were traded in the counter as against an average daily volume of 60,570 shares in the past one quarter.

The stock hit a high of Rs 91 and a low of Rs 86.60 so far during the day. The stock had hit a 52-week high of Rs 96.40 on 26 December 2012. The stock had hit a 52-week low of Rs 58 on 28 March 2012.

The stock had underperformed the market over the past one month till 5 February 2013, falling 5.36% compared with the Sensex's 0.63% fall. The scrip had, however, outperformed the market in past one quarter, rising 16.79% as against Sensex's 4.78% rise.

The small-cap company has an equity capital of Rs 16.94 crore. Face value per share is Rs 2.

J B Chemicals & Pharmaceuticals' net sales rose 33.57% to Rs 199.76 crore in Q3 December 2012 over Q3 December 2011.

J B Chemicals & Pharmaceuticals said it achieved an encouraging performance in Q3 December 2012 due to higher sales and favourable product mix. The profit from operations (after finance cost but before foreign exchange translation gain) surged 163.90% at Rs 24.49 crore in Q3 December 2012 over Q3 December 2011.

All businesses of the company registered growth during the quarter. The domestic formulations business achieved marginal growth but actively promoted products achieved good growth of 15%. The exports to Rest of the World markets achieved good growth of 11% in sales in dollar terms over the same quarter last year. The exports of prescription products to Russia-CIS markets continued to grow during the quarter. The company believes that its Rx portfolio has good potential in this market and would continue to invest in new products and infrastructure for future growth.

J B Chemicals & Pharmaceuticals manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. The company exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The company continues to invest in growing its share in the regulated markets in USA, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.